Alaska Medicaid Pharmacy and Therapeutics Committee
Meeting date April 29, 2016
Frontier Building, 3601 C Street; Room 890/896
Agenda
Call in: 1.800.315.6338. Use access code **24251**#.

1. **Call to Order – Chair**   **8:00 am**
2. **Roll Call**   **8:05 am**
3. **Public Comment**

The Department's methods for class review are to better utilize the time of the P&T Committee.
Classes shown in **Red** are new classes or classes where **new information exists and industry testimony will be taken. Classes shown in **Green** are classes with no significant changes have been noted and no industry testimony will be taken.

**New information includes: new indications or drugs, new warnings, or new head to head clinical evidence.
New dosage forms of available medications

4. Industry comment , discussion & vote on **Red Classes**

Tab 1 -	Androgenic Agents	Tab 2 -	Antibiotics, Inhaled
Tab 3 -	Antifungals, Topical	Tab 4 -	Beta Blockers
Tab 5 -	Bronchodilators, Beta Agonist – Short-acting	Tab 6 -	COPD Agents
Tab 7 -	Immunomodulators, Asthma	Tab 8 -	Immunomodulators, Atopic Dermatitis
Tab 9 -	Intranasal Rhinitis	Tab 10 -	Ophthalmics, Allergic Conjunctivitis
Tab 11 -	Otic Antibiotics		

5. Discussion & vote on **Green Classes**

Tab 1 -	Antihistamines, Minimally Sedating (on step edit)	Tab 2 -	Antivirals, Influenza
Tab 3 -	Bronchodilators, Beta Agonist – Long-acting	Tab 4 -	Epinephrine, Self-injected
Tab 5 -	Fluoroquinolones, Oral	Tab 6 -	Glucocorticoids - Inhaled
Tab 7 -	Hypoglycemics, Alpha-Glucosidase Inhibitors	Tab 8 -	Hypoglycemics, Meglitinides
Tab 9 -	Leukotriene Modifiers	Tab 10 -	Ophthalmic, Antibiotics
Tab 11 -	Ophthalmic, Antibiotic-steroid Combinations	Tab 12 -	Ophthalmic, Anti-inflammatories
Tab 13 -	Ophthalmics, Glaucoma Agents	Tab 14 -	Ophthalmics, Immunomodulator, Restasis
Tab 15 -	Smoking Cessation		

7. **Break as needed –** 15 minutes

8. **Review minutes** from **January 22, 2016** meeting

9. **Comments from Committee Members or Chair**

10. **Adjourn**

Next Meeting Date: TBD September